Amicus Therapeutics, Inc. (FOLD) News

Amicus Therapeutics, Inc. (FOLD): $10.73

-0.01 (-0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FOLD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter FOLD News Items

FOLD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FOLD News Highlights

  • For FOLD, its 30 day story count is now at 17.
  • Over the past 27 days, the trend for FOLD's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • GENE, ARYD and GOLD are the most mentioned tickers in articles about FOLD.

Latest FOLD News From Around the Web

Below are the latest news stories about Amicus Therapeutics Inc that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

STAT+: Unraveling of Amicus spinout spells more trouble for gene therapy field

Amicus Therapeutics called off a planned spinout of its gene therapy division via a combination with a SPAC, spelling more trouble for the gene therapy field.

STAT News | February 24, 2022

Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall

Amicus Therapeutics Inc (NASDAQ: FOLD ) has terminated its plans to spin off its gene therapy assets, citing ''existing market conditions.'' With "market conditions" sinking the planned merger with A RYA Sciences Acquisition Corp IV (NASDAQ: ARYD ), Amicus plans to prioritize its gene therapy pipeline as part of a push to generate $400 million in net savings through 2026. By merging its gene therapy unit with Perceptive Advisors'' ARYA Sciences Acquisition Corp IV, Amicus planned to reduce … Full story available on Benzinga.com

Benzinga | February 24, 2022

Amicus Therapeutics'' (FOLD) CEO John Crowley on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 24, 2022

Amicus, SPAC ARYA mutually terminate business combination for Caritas Therapeutics

ARYA Sciences Acquisition Corp IV (ARYD) and Amicus Therapeutics (FOLD) mutually agreed to terminate their previously announced business combination agreement due to existing…

Seeking Alpha | February 24, 2022

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates

Galafold® Revenue Growth of 17% YoY to $306M in 2021 Galafold Global Sales Growing at Double-Digits (15-20%) with $350M-$365M in 2022 U.S. and EU Regulatory Filings Under Review and Launch Preparations Accelerating for AT-GAA in Pompe Disease Amicus and ARYA IV Mutually Agree to Terminate Planned Business Combination Agreement Strategic Portfolio and R&D Prioritization to Drive ~$400M in Operating Expense Savings Anticipated Through 2026 Profitability Projected in 2023 Conference Call and Webcas

Yahoo | February 24, 2022

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (Nasdaq: FOLD) (“Amicus”) to terminate their previously announced Business Combination Agreement (the “Business Combination Agreement”), effective immediately. “While this is not the outcome we ha

Yahoo | February 24, 2022

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Top 10 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group

In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green’s Redmile Group. If you want to skip our detailed analysis of Green’s history, investment philosophy performance, you can go directly to the Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group. Jeremy Green is the […]

Yahoo | February 17, 2022

Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022

PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2021.

GlobeNewswire | February 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4589 seconds.